- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT00000455
Naltrexone for Early Problem Drinkers
Targeted Naltrexone for Early Problem Drinkers
Early problem drinkers are prevalent in the United States. Recent controlled trials have shown that brief interventions in the primary care setting can reduce drinking and alcohol-related problems in patients who lack evidence of alcohol dependence.
Although naltrexone (Revia) has been approved for the treatment of alcohol dependence, few pharmacotherapy studies have been undertaken with early problem drinkers. This study is an 8-week trial of naltrexone versus placebo, combined with coping skills treatment that either focuses on targeted use of medication or serves as background to daily use of the medication. A total of 160 early problem drinkers recruited through screening in primary care medical settings will be randomly assigned to one of four treatment groups. Followup evaluations will be conducted at the end of treatment and again 3, 6, and 12 months.
Panoramica dello studio
Tipo di studio
Iscrizione
Fase
- Fase 4
Contatti e Sedi
Luoghi di studio
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Stati Uniti, 19103
- Department of Psychiatry, University of Pennsylvania
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Limited to early problem drinkers (i.e., those with no more than mild alcohol dependence).
- Have an average weekly alcohol consumption of greater than or equal to 24 standard drinks for men and 18 standard drinks for women.
- Able to read English at the eighth grade or higher level and show no evidence of significant cognitive impairment.
- Willing to provide a collateral informant for interviews regarding the patient's drinking during the study.
- A woman of child-bearing potential must be non-lactating, practicing a reliable method of birth control, and have a negative pregnancy test prior to initiation of treatment.
- Willing to provide a signed informed consent to participate in the study.
Exclusion Criteria:
- Have a current clinically significant physical disease or abnormality.
- Have a serious psychiatric illness.
- Have a current diagnosis of drug dependence (other than nicotine dependence) or a lifetime diagnosis of opioid dependence.
- A current diagnosis of alcohol dependence that is moderate or greater in severity or a history of alcohol withdrawal, or recurrent use of alcohol to alleviate alcohol withdrawal symptoms.
- Used opioids or other psychoactive medications regularly in the month prior to study enrollment.
- History of hypersensitivity to naltrexone (Revia).
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
Collaboratori e investigatori
Sponsor
Studiare le date dei record
Studia le date principali
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- NIAAAKRA11062
- R01AA011062 (Sovvenzione/contratto NIH degli Stati Uniti)
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su naltrexone
-
University of California, San FranciscoCompletatoSclerosi multiplaStati Uniti
-
Institute of Liver and Biliary Sciences, IndiaNon ancora reclutamentoMalattia epatica da alcolIndia
-
The University of Texas Health Science Center,...National Institute on Drug Abuse (NIDA)CompletatoDisturbi correlati alla cocaina | Abuso di cocainaStati Uniti